Comparative Pharmacology
Head-to-head clinical analysis: MIGLUSTAT versus ZAVESCA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIGLUSTAT versus ZAVESCA.
MIGLUSTAT vs ZAVESCA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miglustat is a glucosylceramide synthase inhibitor that reduces the synthesis of glucosylceramide, a precursor in the biosynthesis of glycosphingolipids. It acts as a competitive inhibitor of the enzyme glucosylceramide synthase, thereby decreasing the accumulation of glucosylceramide and other glycosphingolipids.
Inhibits glucosylceramide synthase, reducing synthesis of glycosphingolipids including glucocerebroside.
100 mg orally three times daily, at regular intervals.
100 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 5–10 hours) in patients with normal renal function; half-life is prolonged in renal impairment, requiring dose adjustment.
Clinical Note
moderateMiglustat + Pregabalin
"The risk or severity of heart failure can be increased when Pregabalin is combined with Miglustat."
Clinical Note
moderateEtacrynic acid + Miglustat
"The therapeutic efficacy of Miglustat can be decreased when used in combination with Etacrynic acid."
Clinical Note
moderateSunitinib + Miglustat
"Sunitinib may increase the hypoglycemic activities of Miglustat."
Clinical Note
moderateLanreotide + Miglustat
6-7 hours; in patients with hepatic impairment, up to 12-15 hours.
Primarily renal excretion of unchanged drug. Following oral administration, approximately 80% of the dose is excreted unchanged in urine, with less than 5% recovered in feces.
Renal (predominantly): 70% unchanged, fecal: 20% as metabolites, biliary: minor.
Category C
Category C
Glucosylceramide Synthase Inhibitor
Glucosylceramide Synthase Inhibitor
"The therapeutic efficacy of Miglustat can be decreased when used in combination with Lanreotide."